Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?

被引：10

作者：

Prytula, Agnieszka ^{[1
]}

Cransberg, Karlien ^{[2
]}

Raes, Ann ^{[1
,3
]}

机构：

[1] Ghent Univ Hosp, Paediat Nephrol & Rheumatol Dept, C Heymanslaan 10, B-9000 Ghent, Belgium

[2] Sophia Childrens Univ Hosp, Erasmus MC, Paediat Nephrol Dept, Rotterdam, Netherlands

[3] Safepedrug Unit, Ghent, Belgium

来源：

PEDIATRIC NEPHROLOGY | 2019年 / 34卷 / 07期

关键词：

Calcineurin inhibitors; CYP3A; CYP3A4; CYP3A5; Vitamin D; Mineral and bone disorder; Renal transplantation; SINGLE NUCLEOTIDE POLYMORPHISMS; CYCLOSPORINE-A; IN-VITRO; BONE LOSS; 1-ALPHA; 25-DIHYDROXYVITAMIN D-3; CALCINEURIN INHIBITORS; GENETIC POLYMORPHISMS; MINERAL METABOLISM; DOSE REQUIREMENTS; LIVER;

D O I：

10.1007/s00467-018-4030-3

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

CYP3A enzymes are involved in the metabolism of calcineurin inhibitor tacrolimus as well as vitamin D. In this review, we summarize the clinical aspects of CYP3A-mediated metabolism of tacrolimus and vitamin D with emphasis on the influence of single-nucleotide polymorphisms on tacrolimus disposition. We describe the utility of 4 hydroxycholesterol as a marker of CYP3A activity. Then, we discuss the possible interaction between calcineurin inhibitors and vitamin D in solid organ transplant recipients. Also, we review other mechanisms which may contribute to side effects of calcineurin inhibitors on bone. Lastly, suggestions for future research and clinical perspectives are discussed.

引用

页码：1201 / 1210

页数：10

共 45 条

[41] PREDICTION OF CLINICAL CYP3A4 INDUCTION USING POOLED HUMAN HEPATOCYTES ON CELL ARRAY 3D-CULTURE PLATE FOR DRUG-METABOLIZING ENZYME INDUCTION STUDIES IN DRUG DISCOVERY
Kuze, Jiro
DRUG METABOLISM REVIEWS, 2014, 45 : 127 - 127
[42] Commentary: The Clinical Impact of the C0/D Ratio and the CYP3A5 Genotype on Outcome in Tacrolimus Treated Kidney Transplant Recipients COMMENT
Tholking, Gerold
Reuter, Stefan
FRONTIERS IN PHARMACOLOGY, 2021, 12
[43] Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations
Zu, Jinliang
Xia, Dongya
Jia, Lihui
Guo, Tao
PHARMAZIE, 2012, 67 (07): : 639 - 644
[44] A Prospective, Double-Blinded, Observational Clinical Cohort Study of the Association Between Tacrolimus Exposure and CYP3A4, CYP3A5 Genotypes in Adult Hematopoietic Stem Cell Transplant Recipients
Trivedi, Jigar S.
Poi, Ming
McBride, Ali
Roddy, Julianna
Poi, Ee
Wang, Jiang
Wang, Danxin
Zhu, Hong
Marek, Elizabeth
Kolli, Shamalatha
Sadee, Wolfgang
Devine, Steven M.
Griffith, Niesha
Phelps, Mitch
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S380 - S380
[45] A Prospective, Open-Label, Observational Clinical Cohort Study of the Association Between Delayed Renal Allograft Function, Tacrolimus Exposure, and CYP3A5 Genotype in Adult Recipients
Kuypers, Dirk R. J.
de Jonge, Hylke
Naesens, Maarten
Vanrenterghem, Yves
CLINICAL THERAPEUTICS, 2010, 32 (12) : 2012 - 2023

← 1 2 3 4 5 →